The Impact of Interleukin-17 Inhibitors on Major Adverse Cardiovascular Events in Psoriasis or Psoriatic Arthritis Patients Naive to Biologic Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

被引:4
作者
Ni, Ruoning [1 ]
Zheng, Jiayi [2 ]
Varghese, Jimmy [3 ]
Kumar, Bharat [4 ,5 ]
机构
[1] Univ Iowa Hosp & Clin, Internal Med, Iowa City, IA USA
[2] Wright Ctr Grad Med Educ, Internal Med, Scranton, PA USA
[3] Northwest Community Healthcare, Rheumatol, Arlington Hts, IL USA
[4] Univ Iowa, Allergy & Immunol, Iowa City, IA 52242 USA
[5] Univ Iowa, Rheumatol, Iowa City, IA 52242 USA
关键词
systematic review and meta analysis; il-17 inhibitor therapy; biological agents; psoriatic-arthritis; psoriasis treatment; SEVERE PLAQUE PSORIASIS; MYOCARDIAL-INFARCTION; DOUBLE-BLIND; RISK; ATHEROSCLEROSIS; SECUKINUMAB; THERAPIES; CELLS; INFLAMMATION; IXEKIZUMAB;
D O I
10.7759/cureus.60980
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The objective of this systematic review is to determine the effects of IL-17 inhibitors on major adverse cardiovascular events (MACEs) in patients with either psoriasis (PsO) or psoriatic arthritis (PsA). A systematic literature search in three databases (Medline, Embase, and the Cochrane Library for Randomized Controlled Trials) was conducted on December 7, 2022 for randomized controlled trials of patients with PsO/PsA treated with IL-17 inhibitors that reported confirmed MACEs. Two reviewers screened titles and abstracts and identified papers for full-text review. Exclusion criteria included trials that included the previous use of biological disease-modifying anti-rheumatic drugs. The Mantel-Haenszel random-effect method was utilized to calculate risk ratios and heterogeneity was measured by chi(2) test and I2 statistics. Funnel plot analysis was undertaken to detect potential publication bias. Of the 919 references identified, nine RCT studies were included in the meta-analysis (n=2,096 patients). There was no statistically significant correlation between the use of IL-17 inhibitors and change in risk of MACEs (Risk Ratio 0.56; 95% CI 0.15 to 2.14; p = 0.40). Subgroup analysis of secukinumab or ixekizumab also did not demonstrate these changes. Additionally, there was no detectable dose-dependent effect of IL-17 inhibitors. In conclusion, IL17 inhibitor use is not correlated with a change in MACE risk in patients with PsO/PsA who previously did not receive biologic disease-modifying anti-rheumatic drugs.
引用
收藏
页数:11
相关论文
共 51 条
[1]  
[Anonymous], 2017, Assessing Risk of Bias in Included Studies
[2]   A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis [J].
Armstrong, April W. ;
Voyles, Stephanie V. ;
Armstrong, Ehrin J. ;
Fuller, Erin N. ;
Rutledge, John C. .
EXPERIMENTAL DERMATOLOGY, 2011, 20 (07) :544-549
[3]   Psoriasis and Major Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Observational Studies [J].
Armstrong, Ehrin J. ;
Harskamp, Caitlin T. ;
Armstrong, April W. .
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2013, 2 (02) :e000062
[4]   The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study [J].
Bagel, Jerry ;
Duffin, Kristina Callis ;
Moore, Angela ;
Ferris, Laura K. ;
Siu, Kimberly ;
Steadman, Jennifer ;
Kianifard, Farid ;
Nyirady, Judit ;
Lebwohl, Mark .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (04) :667-674
[5]   Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial [J].
Baraliakos, Xenofon ;
Gossec, Laure ;
Pournara, Effie ;
Jeka, Slawomir ;
Mera-Varela, Antonio ;
D'Angelo, Salvatore ;
Schulz, Barbara ;
Rissler, Michael ;
Nagar, Kriti ;
Perella, Chiara ;
Coates, Laura C. .
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (05) :582-590
[6]   The IL-17A/IL-17RA Axis Plays a Proatherogenic Role via the Regulation of Aortic Myeloid Cell Recruitment [J].
Butcher, Matthew J. ;
Gjurich, Breanne N. ;
Phillips, Tracy ;
Galkina, Elena V. .
CIRCULATION RESEARCH, 2012, 110 (05) :675-U79
[7]   Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trials [J].
Champs, Benedicte ;
Degboe, Yannick ;
Barnetche, Thomas ;
Cantagrel, Alain ;
Ruyssen-Witrand, Adeline ;
Constantin, Arnaud .
RMD OPEN, 2019, 5 (01)
[8]   Ixekizumab treatment of biologic-naive patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1) [J].
Chandran, Vinod ;
van der Heijde, Desiree ;
Fleischmann, Roy M. ;
Lespessailles, Eric ;
Helliwell, Philip S. ;
Kameda, Hideto ;
Burgos-Vargas, Ruben ;
Erickson, Janelle S. ;
Rathmann, Suchitrita S. ;
Sprabery, Aubrey Trevelin ;
Birt, Julie A. ;
Shuler, Catherine L. ;
Gallo, Gaia .
RHEUMATOLOGY, 2020, 59 (10) :2774-2784
[9]   The Th17/Treg imbalance in patients with acute coronary syndrome [J].
Cheng, Xiang ;
Yu, Xian ;
Ding, Ying-jun ;
Fu, Qing-qing ;
Xie, Jiang-jiao ;
Tang, Ting-ting ;
Yao, Rui ;
Chen, Yong ;
Liao, Yu-hua .
CLINICAL IMMUNOLOGY, 2008, 127 (01) :89-97
[10]   Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE [J].
D'Agostino, Maria Antonietta ;
Schett, Georg ;
Lopez-Rdz, Alejandra ;
Senolt, Ladislav ;
Fazekas, Katalin ;
Burgos-Vargas, Ruben ;
Maldonado-Cocco, Jose ;
Naredo, Esperanza ;
Carron, Philippe ;
Duggan, Anne-Marie ;
Goyanka, Punit ;
Boers, Maarten ;
Gaillez, Corine .
RHEUMATOLOGY, 2022, 61 (05) :1867-1876